|
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Clinical research trials and Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer. Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer clinical trial. Subjects often receive the most expert healthcare possible for their Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer  Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
For Condition: extensive stage small cell lung cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Cancer and Leukemia Group B
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have extensive-stage small cell lung cancer.
Details: OBJECTIVES: I. Determine the complete and overall response rate to paclitaxel in patients with previously untreated extensive stage small cell lung cancer. II. Determine the overall and progression free survival of these patients in response to this treatment regimen. III. Determine the toxicity of this treatment regimen in this patient population. PROTOCOL OUTLINE: This is a multicenter study. Patients receive paclitaxel IV over 3 hours weekly for 6 consecutive weeks. Treatment continues every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, then every 3 months for 2 years, and then annually for 2 years. PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study over 8-11 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically confirmed extensive stage small cell carcinoma of the bronchus; Extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy or contralateral hilar adenopathy - Measurable disease; One lesion that measures at least 20 mm in diameter using conventional techniques or at least 10 mm with spiral CT scan - Lesions not considered measurable include: Bone lesions; Leptomeningeal disease; Ascites; Pleural/pericardial effusion; Cystic lesions; Tumor lesions situated in a previously irradiated area; Abdominal masses not confirmed and followed by imaging techniques - No disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy - Endocrine therapy: No concurrent hormonal therapy except steroids for renal failure or hormones administered for nondisease related conditions - Radiotherapy: At least two weeks since prior radiotherapy; No concurrent palliative radiotherapy - Surgery: Not specified --Patient Characteristics-- - Age: 18 and over - Performance status: CTC 0-2 - Life expectancy: Not specified - Hematopoietic: Granulocyte count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: SGOT less than 2 times upper limit of normal; Bilirubin less than 1.5 mg/dL - Renal: Not specified - Other: Not pregnant or nursing; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarkSocinski, Study Chair, Cancer and Leukemia Group B
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
State University of New York - Upstate Medical University
Syracuse, New York, 13210
United States
Additional Information:
Study ID Numbers: CDR0000067826; CLB-39901
Study Start Date: April 2000
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005646
Other Extensive Stage Small Cell Lung Cancer Studies:
1. Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
2. Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
3. Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
4. Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
5. Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
Related Studies:
Other extensive stage small cell lung cancer Clinical Trials
Other Missouri Clinical Trials
Other Columbia Clinical Trials
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
|
|
|
|
|
|
|
